Browse by category

Welcome to our regular round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have looked far and wide to give you an overview of papers including FundoRing-OAGB modification, magnet-assisted bariatric surgery, Bariclip, ring-augmented sleeve gastrectomy and the SURMOUNT-4 Trial, and more (please note, log-in maybe required to access the full paper). Comparative endoscopic ultrasound assessment of the gastric pouch after F

Just a few months after the world’s first gastric mucosal ablation (GMA) case using MOVIVA (Erbe Elektromedizin) at the Policlinico Universitario Agostino Gemelli in Rome, clinical experience is rapidly expanding across Europe. With around 80 procedures performed within a short timeframe in eight countries, MOVIVA is helping to establish a new era of endoscopic bariatric treatment – offering a less invasive option as obesity rates continue to rise worldwide. Gastric mucosal a

The World Health Organization (WHO) has released its first guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity as a chronic, relapsing disease, to address the growing global health challenge of obesity that affects more than one billion people. In 2024, obesity was associated with 3.7 million deaths worldwide and without decisive action, the number of people with obesity is projected to double by 2030. In September 2025, WHO added GLP-1 ther

Fractyl Health has announced positive 6-month results from its open-label REVEAL-1 Cohort. The REVEAL-1 Cohort is an open-label study in individuals with obesity who have lost at least 15% of their total body weight on a GLP-1 medication and who either need or choose to discontinue GLP-1 therapy. The REVEAL-1 data show that patients who underwent a single Revita procedure after discontinuing GLP-1 therapy maintained both stable body weight and glycaemic control through 6 mont

Ascletis has selected ASC37 oral tablets, its first oral GLP-1R/GIPR/GCGR[1] triple peptide agonist, as a clinical development candidate. Ascletis expects to submit an Investigational New Drug Application (IND) to the FDA for ASC37 oral tablets for the treatment of obesity in the second quarter of 2026. ASC37 oral tablets is the company's first incretin drug candidate developed with its proprietary Peptide Oral Transport ENhancement Technology (POTENT). ASC37, a GLP-1R, GIPR,

A clinical research team at UT Health San Antonio, the academic health centre of The  University of Texas at San Antonio, has been awarded a five-year, nearly $4 million grant from the National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases for a first-of-its-kind study to explore the many roles glucagon plays in human metabolism. Glucagon historically was seen only as insulin’s counterbalance, raising blood sugar during periods when i

For decades, scientists have known that what harms the body often harms the brain. Conditions such as obesity, high blood pressure and insulin resistance strain the body's vascular and metabolic systems. Over time, that stress can speed up cognitive decline and increase the risk of Alzheimer's disease. Now, researchers at Arizona State University and their collaborators report that these effects may begin far earlier than expected. This graphic shows how obesity in young adul

A study conducted at Harvard University has identified a group of metabolites that travel from the intestine to the liver and then to the heart, where they are pumped throughout the body. These metabolites play an important role in controlling metabolic pathways in the liver and insulin sensitivity. This discovery may contribute to future treatments for obesity and type 2 diabetes. Diagram summarising the experiments, which analyzed metabolites present in the peripheral blood

Soybean oil, the most widely consumed cooking oil in the US and a staple of processed foods, contributes to obesity, at least in mice, through a mechanism scientists are now beginning to understand. Soybean oil consumption has increased alongside obesity in the US (Credit: Sonia Deol/UCR) In an experiment conducted at University of California - Riverside, most mice on a high-fat diet rich in soybean oil gained significant weight. However, a group of genetically engineered mic

Novo Nordisk announced the submission of a sNDA to the FDA for a higher dose of semaglutide injection 7.2 mg, to be used along with a reduced calorie diet and increased physical activity for chronic weight management in adults with obesity. Under the CNPV expedited program, review is expected within 1–2 months following the FDA's acceptance of the filing. The sNDA includes results from STEP UP, a 72-week phase 3, randomised, double-blind, placebo-controlled and active-control